

Benedikt Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3442256/publications.pdf>

Version: 2024-02-01

309
papers

10,250
citations

28274

55
h-index

60623

81
g-index

324
all docs

324
docs citations

324
times ranked

7409
citing authors

#	ARTICLE	IF	CITATIONS
1	Socio-demographic, health and drug use characteristics among people with different frequency patterns of cannabis use in Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 425-433.	1.3	1
2	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	4.5	19
3	Proposals for Decriminalization of Illicit Drug Use: Considering a Combination of <i><i>dÃ©jÃ-vu</i></i> , Diversion and Devil-with-many-details for Health-oriented Policy Reform. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 13-15.	1.9	5
4	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75
5	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. <i>Psychopharmacology</i> , 2022, 239, 1211-1230.	3.1	8
6	Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada. <i>International Journal of Drug Policy</i> , 2022, 100, 103480.	3.3	3
7	Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study. <i>BMC Public Health</i> , 2022, 22, 436.	2.9	6
8	Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada. <i>SSM Qualitative Research in Health</i> , 2022, , 100083.	1.5	3
9	Trends in dispensing of individual prescription opioid formulations, Canada 2005â€“2020. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, 27.	2.4	0
10	Health harms of nonâ€“medical prescription opioid use: A systematic review. <i>Drug and Alcohol Review</i> , 2022, 41, 941-952.	2.1	3
11	Evaluating the populationâ€“level effects of oxycodone restrictions on prescription opioid utilization in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	1
12	Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand. <i>International Journal of Drug Policy</i> , 2022, 105, 103712.	3.3	21
13	Spread of Human T-Lymphotropic Virus 1 and 2 Among Relatives of People Who Use Illicit Drugs in Northern Brazil. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	2
14	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
15	Conceptualizing and considering Cannabis-Related â€œHarm-to-Othersâ€: The Role of Cannabis-Related Violence. <i>Substance Use and Misuse</i> , 2022, 57, 1488-1491.	1.4	4
16	Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2022, 17, .	1.6	6
17	Oral HPV among people who use crack-cocaine: prevalence, genotypes, risk factors, and key interventions in a remote Northern Brazilian region. <i>Clinical Oral Investigations</i> , 2021, 25, 759-767.	3.0	8
18	Toward a â€œPost-Legalizationâ€Criminology for Cannabis: A Brief Review and Suggested Agenda for Research Priorities. <i>Contemporary Drug Problems</i> , 2021, 48, 58-74.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 12.	2.2	9
20	“Resurgent”, “twin” or “silent” epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 17.	2.2	31
21	New Zealand's failed cannabis legalization referendum – implications for cannabis policy reform. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 7, 100080.	2.9	5
22	Non-medical cannabis use among Indigenous Canadians: A systematic review of prevalence and associated factors. <i>International Journal of Drug Policy</i> , 2021, 90, 103081.	3.3	2
23	Factors associated with crack-cocaine early initiation: a Brazilian multicenter study. <i>BMC Public Health</i> , 2021, 21, 781.	2.9	4
24	Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil. <i>Viruses</i> , 2021, 13, 926.	3.3	5
25	Food insecurity, chronic pain, and use of prescription opioids. <i>SSM - Population Health</i> , 2021, 14, 100768.	2.7	25
26	Examining a migration-based phenomenon of heroin use in an urban drug scene in Sao Paulo, Brazil. <i>International Journal of Migration, Health and Social Care</i> , 2021, 17, 274-285.	0.5	1
27	Correlations between Changes in Medical Opioid Dispensing and Contributions of Fentanyl to Opioid-Related Overdose Fatalities: Exploratory Analyses from Canada. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7507.	2.6	2
28	Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region. <i>Viruses</i> , 2021, 13, 1380.	3.3	4
29	Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic. <i>International Journal of Drug Policy</i> , 2021, 93, 103166.	3.3	8
30	Drug sentencing in Brazil: factors influencing sentencing outcomes in the criminal courts of Recife/PE. <i>Journal of Criminological Research, Policy and Practice</i> , 2021, ahead-of-print, .	0.3	1
31	Patterns, trends and determinants of medical opioid utilization in Canada 2005–2020: characterizing an era of intensive rise and fall. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 65.	2.2	6
32	Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. <i>European Neuropsychopharmacology</i> , 2021, 51, 106-131.	0.7	10
33	Comparison of Crude Population-Level Indicators of Opioid Use and Related Harm in New Zealand and Ontario (Canada). <i>Pain and Therapy</i> , 2021, 10, 15-23.	3.2	3
34	An overview of select cannabis use and supply indicators pre- and post-legalization in Canada. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 77.	2.2	31
35	Youth Cannabis use and Legalization in Canada - Reconsidering the Fears, Myths and Facts Three Years In. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2021, 30, 191-196.	0.6	5
36	Non-medical opioid use, harms, and interventions in Canada – a 10-year update on an unprecedented substance use-related public health crisis. <i>Drugs: Education, Prevention and Policy</i> , 2020, 27, 118-122.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization. <i>International Journal of Drug Policy</i> , 2020, 76, 102632.	3.3	8
38	Prevalence and risk factors for HIV-1 infection in people who use illicit drugs in northern Brazil. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 213-221.	1.8	16
39	The Lower-Risk Cannabis Use Guidelines™ (LRCUG) recommendations: How are Canadian cannabis users complying?. <i>Preventive Medicine Reports</i> , 2020, 20, 101187.	1.8	12
40	Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007–2016. <i>BMC Health Services Research</i> , 2020, 20, 677.	2.2	8
41	Reflections on the Impending Lawsuits by Governments Against Pharmaceutical Opioid Producers in Canada. <i>Canadian Journal of Addiction</i> , 2020, 11, 25-27.	0.4	1
42	Some notes on the use, concept and socio-political framing of “stigma” focusing on an opioid-related public health crisis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 54.	2.2	23
43	Recent changes in trends of opioid overdose deaths in North America. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 66.	2.2	26
44	Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations. <i>Drug and Alcohol Review</i> , 2020, 39, 555-567.	2.1	13
45	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. <i>Public Health in Practice</i> , 2020, 1, 100046.	1.5	1
46	Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. <i>Microbial Biotechnology</i> , 2020, 15, 1439-1453.	1.7	5
47	Prescription opioid dispensing in Canada: an update on recent developments to 2018. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 68.	2.4	23
48	Lower-Risk Cannabis Use Guidelines: Adherence in Canada and the U.S.. <i>American Journal of Preventive Medicine</i> , 2020, 59, e211-e220.	3.0	9
49	A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. <i>Drug and Alcohol Review</i> , 2020, 39, 737-742.	2.1	4
50	Considering the health and social welfare impacts of non-medical cannabis legalization. <i>World Psychiatry</i> , 2020, 19, 187-188.	10.4	11
51	Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. <i>EClinicalMedicine</i> , 2020, 20, 100294.	7.1	18
52	“Safer opioid distribution” as an essential public health intervention for the opioid mortality crisis – Considerations, options and examples towards broad-based implementation. <i>Public Health in Practice</i> , 2020, 1, 100016.	1.5	5
53	A decade of extreme oscillations in opioid control and availability: implications for public health in a Canadian setting. <i>Journal of Public Health Policy</i> , 2020, 41, 214-220.	2.0	3
54	Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. <i>BMC Public Health</i> , 2020, 20, 143.	2.9	35

#	ARTICLE	IF	CITATIONS
55	Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. <i>Journal of Public Health</i> , 2020, 42, 848-852.	1.8	7
56	Hepatitis B Virus Infection among People Who Use Illicit Drugs: Prevalence, Genotypes and Risk Factors in the State of Amapá, Northern Brazil. <i>Substance Use and Misuse</i> , 2020, 55, 1633-1639.	1.4	6
57	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2020, 10, e038724.	1.9	3
58	The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 14.	2.2	36
59	A century of cannabis control in Canada. , 2020, , 89-115.		27
60	Adiponectin stimulates glucose uptake in mouse blastocysts and embryonic carcinoma cells. <i>Reproduction</i> , 2020, 159, 227-239.	2.6	4
61	New Zealand's 'Cannabis Legalisation and Regulation Bill': an evidence-based assessment and critique of essential regulatory components towards policy outcomes. <i>New Zealand Medical Journal</i> , 2020, 133, 103-111.	0.5	6
62	Tramadol dispensing patterns and trends in Canada, 2007-2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 396-400.	1.9	6
63	Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an "index"™ for monitoring and evaluation. <i>Journal of Public Health</i> , 2019, 41, 412-421.	1.8	50
64	Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 82-87.	1.9	15
65	<i>Drug Policy and the Public Good</i>: a summary of the second edition. <i>Addiction</i> , 2019, 114, 1941-1950.	3.3	7
66	Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region. <i>BMC Infectious Diseases</i> , 2019, 19, 634.	2.9	15
67	Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the state of Pará, northern Brazil. <i>Scientific Reports</i> , 2019, 9, 14750.	3.3	28
68	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 606-621.	2.1	21
69	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. <i>International Journal of Drug Policy</i> , 2019, 73, 96-99.	3.3	3
70	The opioid death crisis in Canada: crucial lessons for public health. <i>Lancet Public Health</i> , The, 2019, 4, e81-e82.	10.0	84
71	Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 550-555.	1.7	12
72	Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. <i>PLoS Medicine</i> , 2019, 16, e1003002.	8.4	98

#	ARTICLE	IF	CITATIONS
73	Assessing service and treatment needs and barriers of youth who use illicit and non-medical prescription drugs in Northern Ontario, Canada. PLoS ONE, 2019, 14, e0225548.	2.5	20
74	Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. Journal of the Canadian Association of Gastroenterology, 2019, 2, 37-43.	0.3	14
75	The New Zealand Government Inquiry Into Mental Health And Addiction's recommendations on substance use: some reflections from the science perspective. New Zealand Medical Journal, 2019, 132, 65-70.	0.5	0
76	Title is missing!. , 2019, 16, e1003002.		0
77	Title is missing!. , 2019, 16, e1003002.		0
78	Title is missing!. , 2019, 16, e1003002.		0
79	Title is missing!. , 2019, 16, e1003002.		0
80	Management of opioid use disorders: a national clinical practice guideline. Cmaj, 2018, 190, E247-E257.	2.0	297
81	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. Contemporary Clinical Trials, 2018, 69, 21-27.	1.8	22
82	Routes of administration for cannabis use – basic prevalence and related health outcomes: A scoping review and synthesis. International Journal of Drug Policy, 2018, 52, 87-96.	3.3	206
83	The “fentanyl epidemic” in Canada – Some cautionary observations focusing on opioid-related mortality. Preventive Medicine, 2018, 107, 109-113.	3.4	65
84	Revisiting the “paradigm shift” in opioid use: Developments and implications 10 years later. Drug and Alcohol Review, 2018, 37, S199-S202.	2.1	32
85	Sustained Reduction in Sexual Behavior that May Pose a Risk of HIV Transmission Following Diagnosis During Early HIV Infection Among Gay Men in Vancouver, British Columbia. AIDS and Behavior, 2018, 22, 2068-2078.	2.7	6
86	Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon. Archives of Virology, 2018, 163, 617-622.	2.1	16
87	Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005–2016. Preventive Medicine, 2018, 116, 112-118.	3.4	13
88	Driving under the influence of prescription opioids: Self-reported prevalence and association with collision risk in a large Canadian jurisdiction. Accident Analysis and Prevention, 2018, 121, 14-19.	5.7	15
89	Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug and Alcohol Dependence, 2018, 189, 76-79.	3.2	32
90	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 2018, 13, e0190768.	2.5	88

#	ARTICLE	IF	CITATIONS
91	Drug Policy and the Public Good. , 2018, , .		48
92	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005â€“2016. Pain Physician, 2018, 1, 219-228.	0.4	40
93	Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier?. Journal of Opioid Management, 2018, 14, 77-79.	0.5	2
94	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. F1000Research, 2018, 7, 1644.	1.6	0
95	Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?. Canadian Family Physician, 2018, 64, e95-e103.	0.4	8
96	Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. Pain Physician, 2018, 21, 219-228.	0.4	21
97	Risk creating and risk reducing: Community perceptions of supervised consumption facilities for illicit drug use. Health, Risk and Society, 2017, 19, 91-111.	1.7	38
98	An easy-to-build, low-budget point-of-care ultrasound simulator: from Linux to a web-based solution. The Ultrasound Journal, 2017, 9, 4.	2.0	14
99	Comparing Medical and Recreational Cannabis Users on Socio-Demographic, Substance and Medication Use, and Health and Disability Characteristics. European Addiction Research, 2017, 23, 129-135.	2.4	16
100	Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence, 2017, 173, 185-190.	3.2	42
101	Substance Use, Health, and Functioning Characteristics of Medical Marijuana Program Participants Compared to the General Adult Population in Ontario (Canada). Journal of Psychoactive Drugs, 2017, 49, 31-38.	1.7	10
102	Reflections on Pollini et al. (2017)â€”Implications for Interventions for Driving While Using Psychotropic Medications With Impairment Risk. Journal of Studies on Alcohol and Drugs, 2017, 78, 814-816.	1.0	6
103	Health outcomes associated with crack-cocaine use: Systematic review and meta-analyses. Drug and Alcohol Dependence, 2017, 180, 401-416.	3.2	114
104	Commentary on Fazel <i>et al</i>. (2017): High levels of substance use disorders among correctional inmatesâ€”some implications for interventions of the review data from Fazel <i>et al</i>.. Addiction, 2017, 112, 1740-1741.	3.3	1
105	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, 1277-1277.	2.7	25
106	Cannabis use, legalization and youth health. Cmaj, 2017, 189, E971-E972.	2.0	8
107	â€”Delistingâ€™ OxyContinÂ® to reduce prescription opioidâ€”related harms in Ontario (Canada)â€”gauging effects 5Â”years later. Pharmacoepidemiology and Drug Safety, 2017, 26, 1040-1043.	1.9	14
108	Fischer et al. Respond. American Journal of Public Health, 2017, 107, e26-e27.	2.7	1

#	ARTICLE	IF	CITATIONS
109	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, e1-e12.	2.7	295
110	The impact of medical and non-medical prescription opioid use on motor vehicle collision risk. <i>Transportation Research Part F: Traffic Psychology and Behaviour</i> , 2017, 47, 155-162.	3.7	9
111	Characterization of hepatitis B virus infection in illicit drug users in the Marajó Archipelago, northern Brazil. <i>Archives of Virology</i> , 2017, 162, 227-233.	2.1	19
112	Legalisation of non-medical cannabis in Canada: will supply regulations effectively serve public health?. <i>Lancet Public Health</i> , The, 2017, 2, e536-e537.	10.0	14
113	The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts". <i>International Journal of Health Policy and Management</i> , 2017, 6, 173-176.	0.9	7
114	Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995. <i>Clinical Drug Investigation</i> , 2016, 36, 519-530.	2.2	37
115	The Cannabis Policy Framework by the Centre for Addiction and Mental Health: A proposal for a public health approach to cannabis policy in Canada. <i>International Journal of Drug Policy</i> , 2016, 34, 1-4.	3.3	28
116	Depression – A major but neglected consequence contributing to the health toll from prescription opioids?. <i>Psychiatry Research</i> , 2016, 243, 331-334.	3.3	19
117	On the relationship between epidemiology and policy. <i>Addiction</i> , 2016, 111, 1687-1688.	3.3	1
118	Policy Measures for Prescription Opioids and Harms: Enough to Protect Public Health? A Comment on Yanovitzky (2016) and Piper et al. (2016). <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 566-567.	1.0	2
119	Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. <i>Cmaj</i> , 2016, 188, 1240-1244.	2.0	80
120	The burden of disease attributable to cannabis use in Canada in 2012. <i>Addiction</i> , 2016, 111, 653-662.	3.3	83
121	Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany. <i>International Journal of Drug Policy</i> , 2016, 29, 57-65.	3.3	14
122	Policy implications of marked reversals of population life expectancy caused by substance use. <i>BMC Medicine</i> , 2016, 14, 42.	5.5	22
123	Treatment of prescription opioid disorders in Canada: looking at the “other epidemic”? <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 12.	2.2	28
124	Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. <i>Journal of Addiction Medicine</i> , 2016, 10, 274-279.	2.6	32
125	Realistically furthering the goals of public health by cannabis legalization with strict regulation: Response to Kalant. <i>International Journal of Drug Policy</i> , 2016, 34, 11-16.	3.3	19
126	Crude estimates of cannabis-attributable mortality and morbidity in Canada – implications for public health focused intervention priorities. <i>Journal of Public Health</i> , 2016, 38, 183-188.	1.8	54

#	ARTICLE	IF	CITATIONS
127	The effectiveness of compulsory drug treatment: A systematic review. <i>International Journal of Drug Policy</i> , 2016, 28, 1-9.	3.3	159
128	Characteristics of clients using a community-based drug treatment service (â€ˆCAPS-ADâ€™™) in Brazil: An exploratory study. <i>International Journal of Drug Policy</i> , 2016, 31, 99-103.	3.3	13
129	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. <i>Drug and Alcohol Dependence</i> , 2016, 161, 298-306.	3.2	70
130	Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. <i>International Journal of Drug Policy</i> , 2016, 27, 23-35.	3.3	32
131	Public Opinion towards Cannabis Control in Ontario: Strong but Diversified Support for Reforming Control of Both Use and Supply. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2016, 58, 443-459.	0.5	10
132	Prescription opioid prescribing, use/misuse, harms and treatment among Aboriginal people in Canada: a narrative review of available data and indicators. <i>Rural and Remote Health</i> , 2016, 16, 3974.	0.5	12
133	Prescription opioids, abuse and public health in Canada: is fentanyl the new centre of the opioid crisis?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1334-1336.	1.9	21
134	Cannabis vaping and public healthâ€™some comments on relevance and implications. <i>Addiction</i> , 2015, 110, 1705-1706.	3.3	11
135	Factors associated with recidivism among adolescents girls in conflict with the law in an institution in BrasÃlia, Federal District, Brazil. <i>Cadernos De Saude Publica</i> , 2015, 31, 2569-2576.	1.0	0
136	Substance Use and Related Harms among Aboriginal People in Canada: A Comprehensive Review. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 1110-1131.	0.8	33
137	Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. <i>International Journal of Drug Policy</i> , 2015, 26, 352-363.	3.3	64
138	Cannabis legalization with strict regulation, the overall superior policy option for public health. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 541-544.	4.7	51
139	Medical marijuana programs â€™ Why might they matter for public health and why should we better understand their impacts?. <i>Preventive Medicine Reports</i> , 2015, 2, 53-56.	1.8	20
140	Considerations towards a population health approach to reduce prescription opioid-related harms (with a primary focus on Canada). <i>Drugs: Education, Prevention and Policy</i> , 2015, 22, 60-65.	1.3	2
141	Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. <i>International Journal of Drug Policy</i> , 2015, 26, 1177-1182.	3.3	35
142	Medical Marijuana programs: Implications for cannabis control policy â€™ Observations from Canada. <i>International Journal of Drug Policy</i> , 2015, 26, 15-19.	3.3	73
143	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. <i>Pain Physician</i> , 2015, 18;4, E605-E614.	0.4	22
144	Recent Developments in Prescription Opioidrelated Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18;4, E662-E662.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. <i>Pain Physician</i> , 2015, 18, E605-14.	0.4	36
146	Recent Developments in Prescription Opioid-related Dispensing and Harm Indicators in Ontario, Canada. <i>Pain Physician</i> , 2015, 18, E659-62.	0.4	12
147	Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: An update 5 years later. <i>Canadian Journal of Public Health</i> , 2014, 105, e146-e149.	2.3	52
148	Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005–2011. <i>Drug and Alcohol Review</i> , 2014, 33, 19-26.	2.1	78
149	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2014, 23, 257-264.	1.4	24
150	Assessing the Impact of Methadone Maintenance Treatment (MMT) on Post-release Recidivism among Male Federal Correctional Inmates in Canada. <i>Criminal Justice and Behavior</i> , 2014, 41, 380-394.	1.8	20
151	Harms of prescription opioid use in the United States. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 43.	2.2	35
152	Impact of Methadone Maintenance Treatment on Women Offenders' Post-Release Recidivism. <i>European Addiction Research</i> , 2014, 20, 192-199.	2.4	31
153	Reflections Regarding Future Cannabis Use Among High-Frequency Users in a Canadian University Student Population. <i>Journal of Research on Adolescence</i> , 2014, 24, 598-607.	3.7	2
154	Considering prescription opioid-related harms in the population: Response to commentaries. <i>Addiction</i> , 2014, 109, 186-188.	3.3	1
155	Increasing public support for supervised injection facilities in Ontario, Canada. <i>Addiction</i> , 2014, 109, 946-953.	3.3	34
156	Comparing key characteristics of young adult crack users in and out-of-treatment in Rio de Janeiro, Brazil. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 2.	2.2	18
157	Exploring sex differences in drug use, health and service use characteristics among young urban crack users in Brazil. <i>International Journal for Equity in Health</i> , 2014, 13, 70.	3.5	33
158	Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: an update with a focus on recent interventions. <i>BMC Health Services Research</i> , 2014, 14, 90.	2.2	77
159	Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: Systematic review and meta-analyses. <i>Addictive Behaviors</i> , 2014, 39, 520-531.	3.0	85
160	Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?. <i>Addiction</i> , 2014, 109, 177-181.	3.3	129
161	A Narrative Review of Recent Developments in Knowledge Translation and Implications for Mental Health Care Providers. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 160-169.	1.9	25
162	Factors Associated with High-Frequency Cannabis Use and Driving among a Multi-site Sample of University Students in Ontario. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2014, 56, 185-200.	0.5	15

#	ARTICLE	IF	CITATIONS
163	Structural barriers in the context of opiate substitution treatment in Germany - a survey among physicians in primary care. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 26.	2.2	20
164	Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 7.	2.2	10
165	Assessing the prevalence of non-medical prescription opioid use in the Canadian general adult population: evidence of large variation depending on survey questions used. <i>BMC Psychiatry</i> , 2013, 13, 6.	2.6	14
166	Patterns, determinants and barriers of health and social service utilization among young urban crack users in Brazil. <i>BMC Health Services Research</i> , 2013, 13, 536.	2.2	32
167	Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. <i>Drug and Alcohol Review</i> , 2013, 32, 276-287.	2.1	44
168	Feasibility and impact of brief interventions for frequent cannabis users in Canada. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 132-138.	2.8	38
169	Crack across the Americas – A massive problem in continued search of viable answers: Exemplary views from the North (Canada) and the South (Brazil). <i>International Journal of Drug Policy</i> , 2013, 24, 631-633.	3.3	34
170	Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. <i>International Journal of Drug Policy</i> , 2013, 24, 432-438.	3.3	69
171	Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. <i>CMAJ Open</i> , 2013, 1, E68-E76.	2.4	11
172	“Hard to crack”: Experiences of community integration among first- and second-generation Asian MSM in Canada.. <i>Cultural Diversity and Ethnic Minority Psychology</i> , 2013, 19, 248-256.	2.0	63
173	Crack Pipe Sharing in Context: How Sociostructural Factors Shape Risk Practices among Noninjection Drug Users. <i>Contemporary Drug Problems</i> , 2013, 40, 481-503.	1.6	13
174	High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005 – 2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 438-442.	1.9	77
175	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2013, 23, n/a-n/a.	1.4	1
176	Use and Nonmedical Use of Prescription Opioid Analgesics in the General Population of Canada and Correlations with Dispensing Levels in 2009. <i>Pain Research and Management</i> , 2013, 18, 69-74.	1.8	27
177	Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. <i>Pain Physician</i> , 2013, 16, E671-84.	0.4	17
178	Characteristics and predictors of health problems from use among high-frequency cannabis users in a Canadian university student population. <i>Drugs: Education, Prevention and Policy</i> , 2012, 19, 49-58.	1.3	6
179	Brief Intervention Experiences of Young High-Frequency Cannabis Users in a Canadian Setting. <i>Contemporary Drug Problems</i> , 2012, 39, 49-72.	1.6	2
180	Drug policy and the public good: evidence for effective interventions. <i>Lancet, The</i> , 2012, 379, 71-83.	13.7	205

#	ARTICLE	IF	CITATIONS
181	The Prevalence of Mental Health and Pain Symptoms in General Population Samples Reporting Nonmedical Use of Prescription Opioids: A Systematic Review and Meta-Analysis. <i>Journal of Pain</i> , 2012, 13, 1029-1044.	1.4	66
182	Correlations between population levels of prescription opioid use and prescription-opioid-related substance use treatment admissions in the USA and Canada since 2001. <i>Public Health</i> , 2012, 126, 749-751.	2.9	23
183	“Opioid Drought”, Canadian-style? Potential implications of the “natural experiment” of delisting Oxycontin in Canada. <i>International Journal of Drug Policy</i> , 2012, 23, 495-497.	3.3	18
184	Police Perceptions of Supervised Consumption Sites (SCSs): A Qualitative Study. <i>Substance Use and Misuse</i> , 2012, 47, 364-374.	1.4	36
185	Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. <i>Drug and Alcohol Dependence</i> , 2012, 124, 172-176.	3.2	14
186	12-month follow-up of an exploratory “brief intervention” for high-frequency cannabis users among Canadian university students. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 15.	2.2	20
187	Increases in the availability of prescribed opioids in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2012, 126, 7-12.	3.2	23
188	Estimating the economic value of British Columbia's domestic cannabis market: Implications for provincial cannabis policy. <i>International Journal of Drug Policy</i> , 2012, 23, 436-441.	3.3	20
189	Use of other opioids during methadone therapy: a population-based study. <i>Addiction</i> , 2012, 107, 776-780.	3.3	23
190	Prescription Opioid Related Misuse, Harms, Diversion and Interventions in Canada: A Review. <i>Pain Physician</i> , 2012, 3S;15, ES191-ES203.	0.4	142
191	Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. <i>Pain Physician</i> , 2012, 15, ES191-203.	0.4	108
192	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. <i>Canadian Journal of Public Health</i> , 2011, 102, 324-327.	2.3	72
193	Non-medical Use of Prescription Opioids Among Ontario Adults: Data From the 2008/2009 CAMH Monitor. <i>Canadian Journal of Public Health</i> , 2011, 102, 330-335.	2.3	22
194	Nonmedical Prescription Opioid Use and Mental Health and Pain Comorbidities: A Narrative Review. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 495-502.	1.9	70
195	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. <i>Addiction</i> , 2011, 106, 1192-1193.	3.3	2
196	NUTT ET AL.'S HARM SCALES FOR DRUGS-ROOM FOR IMPROVEMENT BUT BETTER POLICY BASED ON SCIENCE WITH LIMITATIONS THAN NO SCIENCE AT ALL. <i>Addiction</i> , 2011, 106, 1891-1892.	3.3	26
197	Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. <i>Journal of Viral Hepatitis</i> , 2011, 18, 32-41.	2.0	48
198	Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada – A qualitative exploration. <i>International Journal of Drug Policy</i> , 2011, 22, 292-300.	3.3	40

#	ARTICLE	IF	CITATIONS
199	Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1269-1277.	1.9	72
200	Prevalence and Characteristics of Substance Use Among Chinese and South Asians in Canada. <i>Journal of Ethnicity in Substance Abuse</i> , 2011, 10, 39-47.	0.9	12
201	“What a pity!” Exploring the use of “pitolho” as harm reduction among crack users in Salvador, Brazil. <i>Drugs: Education, Prevention and Policy</i> , 2011, 18, 382-386.	1.3	13
202	Prescription opioid abuse: what is the real problem and how do we fix it?. <i>Canadian Family Physician</i> , 2011, 57, 1241-2, e403-5.	0.4	8
203	Research, Policy Development, and Progress: Antisocial Behaviour and the Automobile. <i>Canadian Public Policy/ Analyse De Politiques</i> , 2010, 36, S81-S93.	1.6	10
204	Assessing the Prevalence of Nonmedical Prescription Opioid Use in the General Canadian Population: Methodological Issues and Questions. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 606-609.	1.9	20
205	A heroin prescription trial: Case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. <i>International Journal of Drug Policy</i> , 2010, 21, 28-35.	3.3	13
206	Typologies of cannabis users and associated characteristics relevant for public health: a latent class analysis of data from a nationally representative Canadian adult survey. <i>International Journal of Methods in Psychiatric Research</i> , 2010, 19, 110-124.	2.1	32
207	Commentary on Ware and St Arnaud-Trempe (2010): Nabilone abuse in Canada? Nature provides an effective prevention program. <i>Addiction</i> , 2010, 105, 504-505.	3.3	1
208	The Global Diversion of Pharmaceutical Drugs-Non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. <i>Addiction</i> , 2010, 105, 2062-2070.	3.3	75
209	Social, health and drug use characteristics of primary crack users in three mid-sized communities in British Columbia, Canada. <i>Drugs: Education, Prevention and Policy</i> , 2010, 17, 333-353.	1.3	21
210	Factors Associated with Treatment Compliance and its Effects on Retention among Participants in a Court-Mandated Treatment Program. <i>Contemporary Drug Problems</i> , 2010, 37, 289-313.	1.6	10
211	Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. <i>Drug and Alcohol Dependence</i> , 2010, 109, 257-260.	3.2	40
212	Cannabis Use in Canada: The Need for a “Public Health” Approach. <i>Canadian Journal of Public Health</i> , 2009, 100, 101-103.	2.3	48
213	How Many People in Canada Use Prescription Opioids Nonmedically in General and Street Drug Using Populations?. <i>Canadian Journal of Public Health</i> , 2009, 100, 104-108.	2.3	22
214	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. <i>Cmaj</i> , 2009, 181, 585-589.	2.0	116
215	Deaths related to the use of prescription opioids. <i>Cmaj</i> , 2009, 181, 881-882.	2.0	32
216	Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. <i>American Journal of Epidemiology</i> , 2009, 170, 783-792.	3.4	85

#	ARTICLE	IF	CITATIONS
217	Fentanyl use among street drug users in Toronto, Canada: Behavioural dynamics and public health implications. <i>International Journal of Drug Policy</i> , 2009, 20, 90-92.	3.3	43
218	Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. <i>Journal of Viral Hepatitis</i> , 2009, 16, 352-358.	2.0	162
219	Thinking the unthinkable: Could the increasing misuse of prescription opioids among street drug users offer benefits for public health?. <i>Public Health</i> , 2009, 123, 145-146.	2.9	10
220	Methamphetamine Injection Independently Predicts Hepatitis C Infection Among Street-Involved Youth in a Canadian Setting. <i>Journal of Adolescent Health</i> , 2009, 44, 302-304.	2.5	30
221	Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada—a latent class analysis. <i>Addiction Research and Theory</i> , 2009, 17, 168-185.	1.9	32
222	Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. <i>Journal of Substance Use</i> , 2009, 14, 75-83.	0.7	14
223	Exploring Drug Sourcing among Regular Prescription Opioid Users in Canada: Data from Toronto and Victoria. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2009, 51, 55-72.	0.5	4
224	A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. <i>Harm Reduction Journal</i> , 2008, 5, 30.	3.2	46
225	Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. <i>Drug and Alcohol Review</i> , 2008, 27, 625-632.	2.1	73
226	Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 340-346.	2.8	15
227	Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. <i>Drug and Alcohol Dependence</i> , 2008, 93, 141-147.	3.2	180
228	Nonmedical Use of Prescription Opioids: Furthering a Meaningful Research Agenda. <i>Journal of Pain</i> , 2008, 9, 490-493.	1.4	14
229	Beyond the barriers: marking the place for marijuana use at a Canadian high school. <i>Journal of Youth Studies</i> , 2008, 11, 47-64.	2.3	10
230	Should heroin be prescribed to heroin misusers? Yes. <i>BMJ: British Medical Journal</i> , 2008, 336, 70-70.	2.3	10
231	Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 29-32.	1.6	74
232	Non-medical Use of Prescription Opioids and Public Health in Canada. <i>Canadian Journal of Public Health</i> , 2008, 99, 182-184.	2.3	39
233	Characterizing the “Awakening Elephant” of Prescription Opioid Misuse in North America: Epidemiology, Harms, Interventions. <i>Contemporary Drug Problems</i> , 2008, 35, 397-426.	1.6	22
234	Reduction in Injection-Related HIV Risk After 6 Months in a Low-Threshold Methadone Treatment Program. <i>AIDS Education and Prevention</i> , 2007, 19, 124-136.	1.1	49

#	ARTICLE	IF	CITATIONS
235	The Costs of Alcohol, Illegal Drugs, and Tobacco in Canada, 2002. <i>Journal of Studies on Alcohol and Drugs</i> , 2007, 68, 886-895.	1.0	126
236	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 335-336.	1.9	0
237	Local Drug-Related Crime Dynamics in a Canadian Multi-Site Sample of Untreated Opioid Users. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2007, 49, 341-373.	0.5	5
238	Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. <i>Drug and Alcohol Dependence</i> , 2007, 88, 1-8.	3.2	129
239	Injection Drug Use, Multiple Hepatitis Virus Infections, and Migration: A German Study. <i>Substance Use and Misuse</i> , 2007, 42, 1353-1365.	1.4	6
240	Prevalence and Associated Factors of Hepatitis C Infection (HCV) in a Multi-site Canadian Population of Illicit Opioid and Other Drug Users (OPICAN). <i>Canadian Journal of Public Health</i> , 2007, 98, 130-133.	2.3	14
241	Multiple viral hepatitis in injection drug users and associated risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 80-85.	2.8	47
242	Illicit opioid use in the 21st century: witnessing a paradigm shift?. <i>Addiction</i> , 2007, 102, 499-501.	3.3	58
243	Crack use in North American cities: the neglected "epidemic". <i>Addiction</i> , 2007, 102, 1340-1341.	3.3	39
244	[Commentary] UNDERSTANDING THE PARAMETERS OF NON-MEDICAL USE OF PRESCRIPTION DRUGS: MOVING BEYOND MERE NUMBERS. <i>Addiction</i> , 2007, 102, 1931-1932.	3.3	10
245	Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2007, 18, 54-61.	3.3	52
246	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. <i>Journal of Urban Health</i> , 2007, 84, 552-562.	3.6	107
247	Drug treatment courts in Canada: an evidence-based review. <i>Hiv/aids Policy * Law Review / Canadian Hiv/aids Legal Network</i> , 2007, 12, 12-7.	0.0	13
248	Determinants of Property Crime Among Illicit Opiate Users Outside of Treatment Across Canada. <i>Deviant Behavior</i> , 2006, 27, 351-376.	1.7	43
249	Change in health-related quality of life of opiate users in low-threshold methadone programs. <i>Journal of Substance Use</i> , 2006, 11, 137-149.	0.7	21
250	An overview of illegal opioid use and health services utilization in Canada. <i>Public Health</i> , 2006, 120, 320-328.	2.9	46
251	Illicit Opioid Use and Treatment for Opioid Dependence: Challenges for Canada and beyond. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 621-623.	1.9	9
252	Health and Social Services Accessed by a Cohort of Canadian Illicit Opioid Users Outside of Treatment. <i>Canadian Journal of Public Health</i> , 2006, 97, 166-170.	2.3	11

#	ARTICLE	IF	CITATIONS
253	Hepatitis C, Illicit Drug Use and Public Health. Canadian Journal of Public Health, 2006, 97, 485-488.	2.3	9
254	Drug-related Overdose Deaths in British Columbia and Ontario, 1992â€“2004. Canadian Journal of Public Health, 2006, 97, 384-387.	2.3	11
255	Illicit Opioid Use and its Key Characteristics: A Select Overview and Evidence from a Canadian Multisite Cohort of Illicit Opioid Users (OPICAN). Canadian Journal of Psychiatry, 2006, 51, 624-634.	1.9	50
256	Crack across Canada: comparing crack users and crack nonâ€“users in a Canadian multiâ€“city cohort of illicit opioid users. Addiction, 2006, 101, 1760-1770.	3.3	81
257	Toking and driving: Characteristics of Canadian university students who drive after cannabis useâ€“an exploratory pilot study. Drugs: Education, Prevention and Policy, 2006, 13, 179-187.	1.3	37
258	Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. European Journal of Gastroenterology and Hepatology, 2006, 18, 1039-1042.	1.6	9
259	Changes in illicit opioid use across Canada. Cmaj, 2006, 175, 1385-1385.	2.0	125
260	Comparing Injecting and Non-Injecting Illicit Opioid Users in a Multisite Canadian Sample (OPICAN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.4	39
261	Determinants of Health-Related Quality of Life of Opiate Users at Entry to Low-Threshold Methadone Programs. European Addiction Research, 2006, 12, 74-82.	2.4	55
262	Patterns of opioid and cocaine co-use: A descriptive study in a Canadian sample of untreated opioid-dependent individuals.. Experimental and Clinical Psychopharmacology, 2005, 13, 303-310.	1.8	28
263	Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). Journal of Urban Health, 2005, 82, 250-266.	3.6	149
264	Prescription Drug Abuse in Canada and the Diversion of Prescription Drugs into the Illicit Drug Market. Canadian Journal of Public Health, 2005, 96, 459-461.	2.3	43
265	Crack Use As a Public Health Problem in Canada. Canadian Journal of Public Health, 2005, 96, 185-188.	2.3	57
266	Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population. American Journal of Public Health, 2005, 95, 1737-1739.	2.7	41
267	Dealing with prostitution in Canada. Cmaj, 2005, 172, 13-14.	2.0	1
268	Policy Changes and the Methadone Maintenance Treatment System for Opioid Dependence in Ontario, 1996 to 2001. Journal of Addictive Diseases, 2005, 24, 39-51.	1.3	23
269	Eyes Wide Shut? â€“ A Conceptual and Empirical Critique of Methadone Maintenance Treatment. European Addiction Research, 2005, 11, 1-14.	2.4	68
270	Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. International Journal of Prisoner Health, 2005, 1, 13-18.	0.9	5

#	ARTICLE	IF	CITATIONS
271	Prostitutes are people too. <i>Lancet, The</i> , 2005, 366, 1264-1265.	13.7	21
272	Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. <i>Addictive Behaviors</i> , 2005, 30, 1025-1028.	3.0	50
273	Self-perceived Health Among Canadian Opiate Users. <i>Canadian Journal of Public Health</i> , 2004, 95, 99-103.	2.3	77
274	Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. <i>Cmaj</i> , 2004, 171, 235-239.	2.0	86
275	How Drug using men who have sex with men account for substance use during Sexual Behaviours: Questioning assumptions of Hiv Prevention and Research. <i>Addiction Research and Theory</i> , 2004, 12, 213-229.	1.9	29
276	Drug use, risk and urban order: examining supervised injection sites (SISs) as "governmentality". <i>International Journal of Drug Policy</i> , 2004, 15, 357-365.	3.3	88
277	Injection Drug Use and the Hepatitis C Virus: Considerations for a Targeted Treatment Approach--The Case Study of Canada. <i>Journal of Urban Health</i> , 2004, 81, 428-447.	3.6	65
278	Cannabis Law Reform in Canada: Is the "Saga of Promise, Hesitation and Retreat" Coming to an End?1. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2003, 45, 265-298.	0.5	38
279	Editorial. <i>European Addiction Research</i> , 2002, 8, 52-53.	2.4	7
280	Heroin-assisted treatment as a response to the public health problem of opiate dependence. <i>European Journal of Public Health</i> , 2002, 12, 228-234.	0.3	82
281	CANADIAN ILLICIT OPIATE USERS' VIEWS ON METHADONE AND OTHER OPIATE PRESCRIPTION TREATMENT: AN EXPLORATORY QUALITATIVE STUDY. <i>Substance Use and Misuse</i> , 2002, 37, 495-522.	1.4	86
282	Compulsory Drug Treatment in Canada: Historical Origins and Recent Developments. <i>European Addiction Research</i> , 2002, 8, 61-68.	2.4	17
283	SUBSTITUTION THERAPY FOR HEROIN ADDICTION. <i>Substance Use and Misuse</i> , 2002, 37, 1149-1178.	1.4	34
284	Heroin prescription for opioid addicts. <i>Lancet, The</i> , 2002, 359, 890.	13.7	0
285	Safer Injection Facilities (SIFs) for Injection Drug Users (IDUs) in Canada. <i>Canadian Journal of Public Health</i> , 2002, 93, 336-338.	2.3	17
286	Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey. <i>Annales De Médecine Interne</i> , 2002, 153, 2S11-21.	0.2	4
287	Some Reflections on the Relationship of Risk, Harm and Responsibility in Recent Tobacco Lawsuits, and Implications for Public Health. <i>Canadian Journal of Public Health</i> , 2001, 92, 7-8.	2.3	1
288	Illicit opiates and crime: Results of an untreated user cohort study in Toronto. <i>Canadian Journal of Criminology and Criminal Justice</i> , 2001, 43, 197-217.	0.3	15

#	ARTICLE	IF	CITATIONS
289	Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals. <i>International Journal of Drug Policy</i> , 2000, 11, 357-370.	3.3	10
290	Social costs of untreated opioid dependence. <i>Journal of Urban Health</i> , 2000, 77, 688-722.	3.6	91
291	Prescriptions, Power and Politics: The Turbulent History of Methadone Maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187.	2.0	55
292	Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time. <i>Cmaj</i> , 2000, 162, 1709-13.	2.0	19
293	Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. <i>Journal of Public Health Policy</i> , 2000, 21, 187-210.	2.0	29
294	Comparing Opiate Users in Methadone Treatment with Untreated Opiate Users: Results of a Follow-up Study with a Toronto Opiate User Cohort. <i>Canadian Journal of Public Health</i> , 1999, 90, 299-303.	2.3	28
295	Prohibition, public health and a window of opportunity: An analysis of Canadian drug policy, 1985-1997. <i>Policy Studies</i> , 1999, 20, 197-210.	1.6	15
296	Illicit Opiates in Toronto: A Profile of Current Users. <i>Addiction Research</i> , 1999, 7, 377-415.	0.6	57
297	Effects of Environmental Pollutants on Reproduction, Euroconference Halle, 11-13 April 1997. <i>Reproduction in Domestic Animals</i> , 1998, 33, 1-3.	1.4	0
298	Exclusion, "risk", and social control: reflections on community policing and public health. <i>Geoforum</i> , 1998, 29, 187-197.	2.5	64
299	Marijuana, juveniles, and the police: What high-school students believe about detection and enforcement. <i>Canadian Journal of Criminology and Criminal Justice</i> , 1998, 40, 401-420.	0.3	8
300	Charting WHO's goals for licit and illicit drugs for the year 2000 are we 'on track'?. <i>Public Health</i> , 1997, 111, 271-275.	2.9	29
301	The Case for a Heroin Substitution Treatment Trial in Canada. <i>Canadian Journal of Public Health</i> , 1997, 88, 367-370.	2.3	43
302	Drugs, Communities, and "Harm Reduction" in Germany: The New Relevance of "Public Health" Principles in Local Responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389.	2.0	16
303	Drugs, communities, and "harm reduction" in Germany: the new relevance of "public health" principles in local responses. <i>Journal of Public Health Policy</i> , 1995, 16, 389-411.	2.0	8
304	Ultrastructural and Autoradiographic study of Preimplantation rabbit embryos grown in conventional or uterine flushing-supplemented culture media. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1992, 28, 337-347.	1.5	3
305	Embryonic development and incidence of aneuploidy in two rabbit strains of different fecundity. <i>Reproduction</i> , 1991, 92, 41-46.	2.6	12
306	Development of preimplantation rabbit embryos in uterine flushing-supplemented culture media. <i>Molecular Reproduction and Development</i> , 1990, 27, 216-223.	2.0	19

#	ARTICLE	IF	CITATIONS
307	Effects of asynchrony on rabbit blastocyst development. <i>Reproduction</i> , 1989, 86, 479-491.	2.6	16
308	Potential risk of light and room temperature exposure to preimplantation embryos. <i>Fertility and Sterility</i> , 1988, 50, 938-944.	1.0	47
309	Assessing service and treatment needs of young people who use illicit and non-medical prescription drugs living in Northern Ontario, Canada. <i>F1000Research</i> , 0, 7, 1644.	1.6	0